Skip to main content Accessibility help
×
Home

Efficacy of ethyl-EPA as a treatment for Huntington disease: a systematic review and meta-analysis

  • Sara Morsy (a1) (a2), Samar Morsy Khalil (a2) (a3), Mohamed Fahmy Doheim (a2) (a4), Mohamed Gomaa Kamel (a2) (a5), Doaa Saeed Mahmoud El-Basiony (a2) (a6), Hossam Idrees Ahmed Hassan (a2) (a7), Ahmed Abdelaziz Eisa (a2) (a8), Cao Thị Anh Ngoc (a2) (a9), Nguyen Phu Dang (a2) (a10), Kenji Hirayama (a11) and Nguyen Tien Huy (a12) (a13) (a14)...

Abstract

Objective:

After MRI studies suggested the efficacy of ethyl-EPA in reducing the progressive brain atrophy in Huntington disease (HD), trials were conducted to test its efficacy as a treatment for HD. Trials that continued for 6 months did not find any significant improvement, urging discontinuation of the drug. However, trials that continued for 12 months indicated improvement of motor functions in these patients.

Methods:

We searched 12 electronic databases to find randomised clinical trials relevant to our inclusion criteria. After screening, only five papers were included. Continuous and binary variables were analysed to compute the pooled mean difference (MD) and risk ratio (RR), respectively. Quality effect model meta-analysis was used as a post hoc analysis for studies at 12 months.

Findings:

Meta-analysis indicated that ethyl-eicosapentaenoic acid (EPA) has no significant effect on any scale of HD at 6 months. At 12 months, two studies suggested significant improvements of the Total Motor Score and Total Motor Score–4 in both fixed and quality effect models [MD = −2.720, 95% CI (−4.76, –.68), p = 0.009; MD = −2.225, 95% CI (−3.842, −0.607), p = 0.007], respectively. Maximal chorea score showed significant results [MD = −1.013, 95% CI (−1.793, −0.233), p = 0.011] in only fixed-effect model, while no improvement was detected for Stroop colour naming test or symbol digit modality.

Conclusion:

Meta-analysis indicated a significant improvement of motor scores only after 12 months. These results should be interpreted cautiously because only two studies had assessed the efficacy of ethyl-EPA after 12 months with one of them having a 6-month open-label phase.

Copyright

Corresponding author

Author for correspondence: Nguyen Tien Huy, Email: nguyentienhuy@tdtu.edu.vn

References

Hide All
Bauer, I, Crewther, S, Pipingas, A, Sellick, L and Crewther, D (2014) Does omega-3 fatty acid supplementation enhance neural efficiency? A review of the literature. Human Psychopharmacology 29(1), 818.
Biglan, KM, Ross, CA, Langbehn, DR, Aylward, EH, Stout, JC, Queller, S, Carlozzi, N, Duff, K, Beglinger, LJ and Paulsen, JS (2009) Motor abnormalities in premanifest persons with Huntington’s disease: the PREDICT-HD study. Movement Disorders 24(12), 17631772.
Block, RC, Dorsey, ER, Beck, CA, Brenna, JT and Shoulson, I (2010) Altered cholesterol and fatty acid metabolism in Huntington disease. Journal of Clinical Lipidology 4(1), 1723.
Bos, DJ, van Montfort, SJT, Oranje, B, Durston, S and Smeets, PAM (2016) Effects of omega-3 polyunsaturated fatty acids on human brain morphology and function: what is the evidence? European Neuropsychopharmacology 26(3), 546561.
Carlozzi, NE, Hahn, EA, Goodnight, SM, Kratz, AL, Paulsen, JS, Stout, JC, Frank, S, Miner, JA, Cella, D, Gershon, RC, Schilling, SG and Ready, RE (2017) Patient-reported outcome measures in Huntington disease: quality of life in neurological disorders (Neuro-QoL) social functioning measures. Psychological Assessment. 30(4), 450458.
Clifford, JJ, Drago, J, Natoli, AL, Wong, JY, Kinsella, A, Waddington, JL and Vaddadi, KS (2002) Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington’s disease. Neuroscience 109(1), 8188.
Cowan, CM and Raymond, LA (2006) Selective neuronal degeneration in Huntington’s disease. Current Topics in Developmental Biology 75, 2571.
DerSimonian, R and Laird, N (1986) Meta-analysis in clinical trials. Controlled Clinical Trials 7(3), 177188.
Divino, V, Dekoven, M, Warner, JH, Giuliano, J, Anderson, KE, Langbehn, D, and Lee, WC (2013) The direct medical costs of Huntington’s disease by stage. a retrospective commercial and Medicaid claims data analysis. Journal of Medical Economics 16(8), 10431050.
Doi, SAR and Thalib, L (2008) A quality-effects model for meta-analysis. Epidemiology 19(1), 94100.
Estrada Sanchez, AM, Mejia-Toiber, J and Massieu, L (2008) Excitotoxic neuronal death and the pathogenesis of Huntington’s disease. Archives of Medical Research 39(3), 265276.
Ferreira, JJ, Rosser, A, Craufurd, D, Squitieri, F, Mallard, N and Landwehrmeyer, B (2015) Ethyl-eicosapentaenoic acid treatment in Huntington’s disease: a placebo-controlled clinical trial. Movement Disorders 30(10), 14261429.
Follmann, D, Elliott, P, Suh, I and Cutler, J (1992) Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology 45(7), 769773.
Frank, S (2014) Treatment of Huntington’s disease. Neurotherapeutics 11(1), 153160.
Frank, S, Testa, CM, Stamler, D, Kayson, E, Davis, C, Edmondson, MC, Kinel, S, Leavitt, B, Oakes, D, O’Neill, C, Vaughan, C, Goldstein, J, Herzog, M, Snively, V, Whaley, J, Wong, C, Suter, G, Jankovic, J, Jimenez-Shahed, J, Hunter, C, Claassen, DO, Roman, OC, Sung, V, Smith, J, Janicki, S, Clouse, R, Saint-Hilaire, M, Hohler, A, Turpin, D, James, RC, Rodriguez, R, Rizer, K, Anderson, KE, Heller, H, Carlson, A, Criswell, S, Racette, BA, Revilla, FJ, Nucifora, F Jr, Margolis, RL, Ong, M, Mendis, T, Mendis, N, Singer, C, Quesada, M, Paulsen, JS, Brashers-Krug, T, Miller, A, Kerr, J, Dubinsky, RM, Gray, C, Factor, SA, Sperin, E, Molho, E, Eglow, M, Evans, S, Kumar, R, Reeves, C, Samii, A, Chouinard, S, Beland, M, Scott, BL, Hickey, PT, Esmail, S, Fung, WL, Gibbons, C, Qi, L, Colcher, A, Hackmyer, C, McGarry, A, Klos, K, Gudesblatt, M, Fafard, L, Graffitti, L, Schneider, DP, Dhall, R, Wojcieszek, JM, LaFaver, K, Duker, A, Neefus, E, Wilson-Perez, H, Shprecher, D, Wall, P, Blindauer, KA, Wheeler, L, Boyd, JT, Houston, E, Farbman, ES, Agarwal, P, Eberly, SW, Watts, A, Tariot, PN, Feigin, A, Evans, S, Beck, C, Orme, C, Edicola, J, Christopher, E (2016) Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. The Journal of the American Medical Association 316(1), 4050.
Fu, R, Vandermeer, BW, Shamliyan, TA, O’Neil, ME, Yazdi, F, Fox, SH and Morton, SC (2008) Handling continuous outcomes in quantitative synthesis. In Rockville (MD).
Gusella, JF, MacDonald, ME, Ambrose, CM and Duyao, MP (1993) Molecular genetics of Huntington’s disease. Archives of Neurology 50(11), 11571163.
Higgins, JP, Altman, DG, Gøtzsche, PC, Jüni, P, Moher, D, Oxman, AD, Savovic, J, Schulz, KF, Weeks, L and Sterne, JA (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. The British Medical Journal 343, d5928.
Hsu, Y-M and Yin, M-C (2016) EPA or DHA enhanced oxidative stress and aging protein expression in brain of d-galactose treated mice. BioMedicine 6(3), 17.
Huntington Study Group (1996) Unified Huntington’s Disease Rating Scale: reliability and consistency. Movement Disorders 11(2), 136142.
Huntington Study Group TREND-HD Investigators (2008) Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Archives of Neurology 65(12), 15821589.
Jones, C, Busse, M, Quinn, L, Dawes, H, Drew, C, Kelson, M, Hood, K, Rosser, A and Edwards, RT (2016) The societal cost of Huntington’s disease: are we underestimating the burden? European Journal of Neurology 23(10), 15881590.
Katsuno, M, Banno, H, Suzuki, K, Takeuchi, Y, Kawashima, M, Tanaka, F, Adachi, H and Sobue, G (2008) Molecular genetics and biomarkers of polyglutamine diseases. Current Molecular Medicine 8(3), 221234.
Kawashima, A, Harada, T, Kami, H, Yano, T, Imada, K and Mizuguchi, K (2010) Effects of eicosapentaenoic acid on synaptic plasticity, fatty acid profile and phosphoinositide 3-kinase signaling in rat hippocampus and differentiated PC12 cells. Journal of Nutritional Biochemistry 21(4), 268277.
Kenney, C, Hunter, C, Davidson, A and Jankovic, J (2007) Short-term effects of tetrabenazine on chorea associated with Huntington’s disease. Movement Disorder 22(1), 1013.
Kirkwood, SC, Siemers, E, Bond, C, Conneally, PM, Christian, JC and Foroud, T (2000) Confirmation of subtle motor changes among presymptomatic carriers of the Huntington disease gene. Archives of Neurology 57(7), 10401044.
Klempir, J,Klempirova, O, Spackova, N, Zidovska, J and Roth, J. (2006) Unified Huntington’s disease rating scale: clinical practice and a critical approach. Funct Neurol 21(4), 217221.
Langbehn, DR, Hayden, M, Paulsen, JS and Group the P-HI of the HS (2010) CAG-repeat length and the age of onset in Huntington Disease (HD): a review and validation study of statistical approaches. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 153B(2) , 397408. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048807/.
Liberati, A, Altman, DG, Tetzlaff, J, Mulrow, C, Gøtzsche, PC, Ioannidis, JP, Clarke, M, Devereaux, PJ, Kleijnen, J and Moher, D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. The British Medical Journal 339, b2700.
Liu, G, Bibus, DM, Bode, AM, Ma, W-Y, Holman, RT, Dong, Z. (2001) Omega 3 but not omega 6 fatty acids inhibit AP-1 activity and cell transformation in JB6 cells. Proceedings of the National Academy of Sciences of the United States of America 98(13), 75107515.
Liu, YF (1998) Expression of polyglutamine-expanded Huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line. Journal of Biological Chemistry 273(44), 2887328877.
Louis, ED, Lee, P, Quinn, L and Marder, K (1999) Dystonia in Huntington’s disease: prevalence and clinical characteristics. Movement Disorders 14(1), 95101.
Loy, CT and McCusker, EA (2013) Is a motor Criterion Essential for the Diagnosis of Clinical Huntington Disease? PLoS Currents 5, ecurrents.hd.f4c66bd51e8db11f55e1701af937a419. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644296/.
Lynch, AM, Moore, M, Craig, S, Lonergan, PE, Martin, DS andLynch, MA (2003) Analysis of interleukin-1 beta-induced cell signaling activation in rat hippocampus following exposure to gamma irradiation. Protective effect of eicosapentaenoic acid. Journal of Biological Chemistry 278(51), 5107551084.
Mantel, N and Haenszel, W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 22(4), 719748.
Murck, H and Manku, M (2007) Ethyl-EPA in Huntington disease: potentially relevant mechanism of action. Brain Research Bulletin 72(2–3), 159164.
Paulsen, JS (2011) Cognitive impairment in Huntington disease: diagnosis and treatment. Current Neurology and Neuroscience Reports 11(5), 474483.
Paulsen, JS, Langbehn, DR, Stout, JC, Aylward, E, Ross, CA, Nance, M, Guttman, M, Johnson, S, MacDonald, M, Beglinger, LJ, Duff, K, Kayson, E, Biglan, K, Shoulson, I, Oakes, D and Hayden, M (2008) Detection of Huntington’s disease decades before diagnosis: the Predict-HD study. Journal of Neurology, Neurosurgery, and Psychiatry 79(8), 874880.
Penney, JB Jr, Young, AB, Shoulson, I, Starosta-Rubenstein, S, Snodgrass, SR, Sanchez-Ramos, J, Ramos-Arroyo, M, Gomez, F, Penchaszadeh, G, Alvir, J, and Esteves, J (1990) Huntington’s disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Movement Disorders 5(2), 9399.
Philbrick, DJ, Mahadevappa, VG, Ackman, RG and Holub, BJ (1987) Ingestion of fish oil or a derived n-3 fatty acid concentrate containing eicosapentaenoic acid (EPA) affects fatty acid compositions of individual phospholipids of rat brain, sciatic nerve and retina. Journal of Nutrition 117(10), 16631670.
Pringsheim, T, Wiltshire, K, Day, L, Dykeman, J, Steeves, T and Jette, N (2012) The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Movement Disorders 27(9), 10831091.
Puri, BK, Bydder, GM, Counsell, SJ, Corridan, BJ, Richardson, AJ, Hajnal, JV, Appel, C, Mckee, HM, Vaddadi, KS and Horrobin, DF (2002) MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. NeuroReport 13(1), 123126.
Puri, BK, Bydder, GM, Manku, MS, Clarke, A, Waldman, AD and Beckmann, CF (2008) Reduction in cerebral atrophy associated with ethyl-eicosapentaenoic acid treatment in patients with Huntington’s disease. Journal of International Medical Research 36(5), 896905.
Puri, BK, Leavitt, BR, Hayden, MR, Ross, CA, Rosenblatt, A, Greenamyre, JT, Hersch, S, Vaddadi, KS, Sword, A, Horrobin, DF, Manku, M and Murck, H (2005) Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 65(2), 286292.
Pusceddu, MM, Kelly, P, Stanton, C, Cryan, JF and Dinan, TG (2016) N-3 Polyunsaturated fatty acids through the lifespan: implication for psychopathology. The International Journal of Neuropsychopharmacology 19(12), pyw078.
Shah, PB (2011) Intention-to-treat and per-protocol analysis. Canadian Medical Association Journal 183(6), 696. Available at https://www.ncbi.nlm.nih.gov/pubmed/21464181
Siesling, S, van Vugt, JP, Zwinderman, KA, Kieburtz, K and Roos, RA (1998) Unified Huntington’s disease rating scale: a follow up. Movement Disorders 13(6), 915919.
Siesling, S, Zwinderman, AH, van Vugt, JP, Kieburtz, K and Roos, RA (1997) A shortened version of the motor section of the Unified Huntington’s Disease Rating Scale. Movement Disorders 12(2), 229234.
Titova, OE, Sjögren, P, Brooks, SJ, Kullberg, J, Ax, E, Kilander, L, Riserus, U, Cederholm, T, Larsson, EM, Johansson, L and Ahlström, H (2013) Dietary intake of eicosapentaenoic and docosahexaenoic acids is linked to gray matter volume and cognitive function in elderly. Age (Dordr) 35(4), 14951505.
Vaccarino, AL, Anderson, K, Borowsky, B, Duff, K, Giuliano, J, Guttman, M, Ho, AK, Orth, M, Paulsen, JS, Sills, T and Van Kammen, DP (2011) An item response analysis of the motor and behavioral subscales of the unified Huntington’s disease rating scale in huntington disease gene expansion carriers. Movement Disorders 26(5), 877884.
Van Raamsdonk, JM, Pearson, J, Rogers, DA, Lu, G, Barakauskas, VE, Barr, AM, Honer, WG, Hayden, MR and Leavitt, BR (2005) Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Experimental Neurology 196(2), 266272.
van Rijkom, HM, Truin, GJ and van ‘t Hof, MA (1998) A meta-analysis of clinical studies on the caries-inhibiting effect of fluoride gel treatment. Caries Research 32(2), 8392.
Waitzberg, DL and Garla, P (2014). Nutrición Hospitalaria 30(3), 467477.
Walker, FO (2017) Huntington’s disease. Lancet 369(9557), 218228.
Yasuda, S, Inoue, K, Hirabayashi, M, Higashiyama, H, Yamamoto, Y, Fuyuhiro, H, Komure, O, Tanaka, F, Sobue, G, Tsuchiya, K, Hamada, K, Sasaki, H, Takeda, K, Ichijo, H and Kakizuka, A (1999) Triggering of neuronal cell death by accumulation of activated SEK1 on nuclear polyglutamine aggregations in PML bodies. Genes to Cells 4(12), 743756.
Zhao, Y and Chen, LH. (2005) Eicosapentaenoic acid prevents lipopolysaccharide-stimulated DNA binding of activator protein-1 and c-Jun N-terminal kinase activity. Journal of Nutritional Biochemistry 16(2), 7884.

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed